{"title":"细胞癌免疫治疗在肝移植人群HCC：一个有吸引力的治疗选择在未来十年","authors":"Dongdong Yu, Shuchan Li, Hao Chen, Lidong Wang","doi":"10.1111/ctr.70313","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Immunocytotherapy has emerged as a promising therapeutic tool against hepatocellular carcinoma (HCC). Liver transplantation (LT) remains the primary option for curing HCC; however, post-transplant tumor recurrence and the development of new malignancies significantly impact patient prognosis. The application of immune cell therapy in LT for HCC may reestablish antitumor immunity following transplantation without increasing the risk of rejection. In this review, we provide a concise overview of the suppressive tumor-immune status and its impact on tumor recurrence and the development of neoplastic tumors after LT for HCC. We also examine the latest cellular cancer immunotherapy regimens for solid tumors, with a particular focus on HCC, and discuss their limitations. Finally, we summarize the challenges of applying cellular cancer immunotherapy in LT, including the potential induction of acute rejection and the suppressive effects of immunosuppressive agents, as well as potential coping strategies. In conclusion, cellular cancer immunotherapy may offer a potentially effective treatment for tumor recurrence in LT for HCC.</p>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 9","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade\",\"authors\":\"Dongdong Yu, Shuchan Li, Hao Chen, Lidong Wang\",\"doi\":\"10.1111/ctr.70313\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Immunocytotherapy has emerged as a promising therapeutic tool against hepatocellular carcinoma (HCC). Liver transplantation (LT) remains the primary option for curing HCC; however, post-transplant tumor recurrence and the development of new malignancies significantly impact patient prognosis. The application of immune cell therapy in LT for HCC may reestablish antitumor immunity following transplantation without increasing the risk of rejection. In this review, we provide a concise overview of the suppressive tumor-immune status and its impact on tumor recurrence and the development of neoplastic tumors after LT for HCC. We also examine the latest cellular cancer immunotherapy regimens for solid tumors, with a particular focus on HCC, and discuss their limitations. Finally, we summarize the challenges of applying cellular cancer immunotherapy in LT, including the potential induction of acute rejection and the suppressive effects of immunosuppressive agents, as well as potential coping strategies. In conclusion, cellular cancer immunotherapy may offer a potentially effective treatment for tumor recurrence in LT for HCC.</p>\\n </div>\",\"PeriodicalId\":10467,\"journal\":{\"name\":\"Clinical Transplantation\",\"volume\":\"39 9\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70313\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70313","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade
Immunocytotherapy has emerged as a promising therapeutic tool against hepatocellular carcinoma (HCC). Liver transplantation (LT) remains the primary option for curing HCC; however, post-transplant tumor recurrence and the development of new malignancies significantly impact patient prognosis. The application of immune cell therapy in LT for HCC may reestablish antitumor immunity following transplantation without increasing the risk of rejection. In this review, we provide a concise overview of the suppressive tumor-immune status and its impact on tumor recurrence and the development of neoplastic tumors after LT for HCC. We also examine the latest cellular cancer immunotherapy regimens for solid tumors, with a particular focus on HCC, and discuss their limitations. Finally, we summarize the challenges of applying cellular cancer immunotherapy in LT, including the potential induction of acute rejection and the suppressive effects of immunosuppressive agents, as well as potential coping strategies. In conclusion, cellular cancer immunotherapy may offer a potentially effective treatment for tumor recurrence in LT for HCC.
期刊介绍：
Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include:
Immunology and immunosuppression;
Patient preparation;
Social, ethical, and psychological issues;
Complications, short- and long-term results;
Artificial organs;
Donation and preservation of organ and tissue;
Translational studies;
Advances in tissue typing;
Updates on transplant pathology;.
Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries.
Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
